IMVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Immunovant Inc (IMVT) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is experiencing a pre-market decline of -3.00%, and technical indicators suggest a mixed trend. While hedge funds are increasing their positions and analysts have raised price targets, the company's financial performance remains weak with no revenue growth and declining EPS. The lack of recent AI Stock Picker or SwingMax signals further supports a cautious approach. For now, it is better to hold and wait for clearer positive signals or improved financial performance.
The MACD is negative and expanding (-0.0549), indicating bearish momentum. RSI is neutral at 43.738, and moving averages (SMA_5 > SMA_20 > SMA_200) suggest a bullish trend. However, the pre-market price is below the key pivot level of 25.937, with support at 24.401 and resistance at 27.474.
The company has a strong cash position of $994.5 million and is advancing its IMVT-1402 product in a competitive market.
The stock is down -3.00% in pre-market trading. Financial performance is weak, with no revenue growth, declining EPS (-19.74% YoY), and a net income loss of -$110.6 million. The recent $550 million stock offering caused a 7% drop in stock price, indicating dilution concerns.
In Q3 2026, Immunovant reported no revenue growth (0.00% YoY), a net income loss of -$110.6 million (-0.44% YoY), and a decline in EPS to -0.61 (-19.74% YoY). The company has a strong cash position of $994.5 million but faces challenges in profitability.
Analysts are mixed but leaning positive. Guggenheim raised its price target to $44 and maintains a Buy rating, while Truist raised its target to $23 but keeps a Hold rating. Wolfe Research upgraded the stock to Outperform in January 2026.
